23 min listen
A Venture Capitalist’s View of the Current Biotech Landscape
FromThe Bio Report
ratings:
Length:
44 minutes
Released:
Sep 6, 2023
Format:
Podcast episode
Description
Earlier this year, the venture capital firm SR One closed a $600 million fund, its second since spinning out from the pharmaceutical giant GSK. Despite the difficult investment landscape today for biotechs, it’s a reminder that significant capital is available to be deployed. We spoke to Simeon George, CEO and managing partner for SR One, about the firm’s investment approach, how the current landscape is causing venture capitalists and therapeutics developers to think differently, and what advice he’d offer entrepreneurs seeking to raise money today.
Released:
Sep 6, 2023
Format:
Podcast episode
Titles in the series (100)
Brittany Maynard and the Debate over the Right to Die: Brittany Maynard, a 29-year-old woman with terminal brain cancer who chose to end her own life with a lethal dose of medication, sparked a renewed discussion of so-called death with dignity laws. Maynard had become visible on social and traditional m... by The Bio Report